The demand for modified-release formulations is driven by many factors related to both patient and therapeutic needs. For most conditions, patients generally demand either once-daily or twice-daily treatments, requiring sustained drug concentrations throughout the treatment period.
Modified-release formulations are designed to deliver your drug over a defined period of time and/or to a particular region of the body. By doing this, drug delivery can be optimized to balance therapeutic need, manage adverse event (AE) profiles, and reduce dosing frequency, which contribute to improved patient compliance.
Quotient Sciences has extensive experience in designing modified-release formulations, from gastro-retention to sustained-release and pulsatile-release formats. Learn more about how we can help tailor your programs in our latest info sheet.
Modified-release format | Objective | Formulation technology |
Gastro-retention |
|
Swellable tablets (monolithic, bilayer, trilayer) |
Gastro-resistant |
|
Enteric-coated tablets or capsules |
Sustained or extended release |
|
Matrix tablets, coated tablets, or multiparticulates |
Targeted or controlled delivery |
|
Tablets, capsules, or multiparticulates |
Biphasic release |
|
Bilayer tablets or multiparticulates |
Pulsatile release |
|
Bilayer tablets or multiparticulates |
Expert support for your modified-release programs
Although modified-release formulations can offer many therapeutic benefits for both drug developers and patients, there are several challenges to overcome when trying to develop this type of formulation. With over 30 years of expertise, Quotient Sciences can help with even the most challenging modified-release programs.
Access our latest info sheet to find out how our modified-release formulation strategies and technologies can help your molecule achieve clinical and commercial success.